Parkinson’s Disease and Related Disorders pp 133-142
Potential sources of increased iron in the substantia nigra of parkinsonian patients
Histopathological, biochemical and in vivo brain imaging techniques, such as magnetic resonance imaging and transcranial sonography, revealed a consistent increase of substantia nigra (SN) iron in Parkinson’s disease (PD). Increased iron deposits in the SN may have genetic and non-genetic causes. There are several rare movement disorders associated with neurodegeneration, and genetic abnormalities in iron regulation resulting in iron deposition in the brain. Non-genetic causes of increased SN iron may be the result of a disturbed or open blood-brain-barrier, local changes in the normal iron-regulatory systems, intraneuronal transportation of iron from iron-rich area into the SN and release of iron from intracellular iron storage molecules. Major iron stores are ferritin and haemosiderin in glial cells as well as neuromelanin in neurons. Age- and disease dependent overload of iron storage proteins may result in iron release upon reduction. Consequently, the low molecular weight chelatable iron complexes may trigger redox reactions leading to damage of biomolecules. Additionally, upon neurodegeneration there is strong microglial activation which can be another source of high iron concentrations in the brain.
Unable to display preview. Download preview PDF.
- Davidson LA, Lonnerdal B (1989) Fe-saturation and proteolysis of human lactoferrin: effect on brushborder receptor mediated uptake of Fe and Mn. Am J Physiol 2257: G930–G934Google Scholar
- Double KL, Riederer P, Gerlach M (1999) The significance of neuromelanin for neurodegeneration in Parkinson’s disease. Drug News Perspect 12: 333–340Google Scholar
- Double KL, Gerlach M, Youdim MBH, Riederer P (2000) Impaired iron homeostasis in Parkinson’s disease. J Neural Transm [Suppl] 60: 37–58Google Scholar
- Gerlach M, Double K, Götz ME, Youdim MBH, Riederer P (2006) The role of iron in the pathogenesis of Parkinson’s disease. In: Sigel A, Sigel H, Sigel RKO (eds) Neurodegenerative Diseases and Metal Ions, Vol 1 of Metal Ions in Life Sciences. Wiley & Sons, Chichester (in press)Google Scholar
- Jellinger K (1989) Pathology of Parkinson’s syndrome. In: Calne DB (eds) Handbook of experimental pharmacology, vol 88. Springer, Berlin Heidelberg, pp 47–112Google Scholar
- Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MBH (1995) Chemical evidence for 6-hydroxy-dopamine to be an endogenous toxic factor in the pathogenesis of Parkinson’s disease. J Neural Transm [Suppl] 46: 297–314Google Scholar
- Lapenna D, Degioia S, Ciofani G, Cuccurullo F (1995) Captopril induces iron release from ferritin and oxidative stress. J Pharm Pharmacol 47: 59–61Google Scholar
- Lopiano L, Digilio G, Fasano M, Giraudo S, Rizzone M, Torre E, Bergamasco B (1999) Iron and neuromelanin in Parkinson’s disease. J Neural Transm 106: XXIVGoogle Scholar
- Riederer P (2004) Views on neurodegeneration as a basis for neuroprotective strategies. Med Sci Monit 10(12): RA287–RA290Google Scholar
- Riederer P, Sofic E, Rausch WD, Kruzik P, Youdim MBH (1985) Dopaminforschungheute undmorgen — L-Dopa in der Zukunft. In: Riederer P, Vmek H (eds) L-Dopa-Substitution der Parkinson-Krankheit. Geschichte-Gegenwart-Zukunft. Springer, Wien New York, pp 127–144Google Scholar